吉西他滨联合顺铂治疗晚期非小细胞肺癌临床研究

Clinical study of combination chemotherapy with gemcitabine and cisplatin in the treatment of advanced non-small-cell lung cancer

目的比较晚期非小细胞肺癌采用吉西他滨加顺铂与长春瑞滨加顺铂化疗的疗效、生存期和毒副作用.方法 60例晚期非小细胞肺癌患者随机分为两组,A组30例,采用吉西他滨加顺铂;B组30例,采用长春瑞滨加顺铂,进行疗效分析和毒副作用比较.结果 A组CR 3例,PR 15例,总有效率60.0%,1年生存率33.3%,中位生存期9.4个月,肿瘤进展时间2～20个月,Karnofsky平均提高15分;B组CR 1例,PR 13例,总有效率46.7%,1年生存率16.7%,中位生存期6.4个月,肿瘤进展时间3～16个月,Karnofsky平均提高10分,两组间总有效率、1年生存率差异有显著性(P<0.05).最常见的毒副反应为骨髓抑制,A组为血小板减少,B组为白细胞减少.结论吉西他滨加顺铂治疗晚期非小细胞肺癌疗效明确,耐受性好.

Objective To evaluate and compare the therapeutic efficacy and toxicity between combination of gemcitabine and cisplatin （group A） and combination of navelbine and cisplatin （ group B） in advanced non-small-cell lung cancer （NSCLC）. Methods Sixty patients with advanced NSCLC were enrolled into the study with 30 patients in A group and 30 patients in B group. Results Objective response rate of 60.0% was observed in group A. The 1-year survival rate was 33.3% and the median survival duration was 9.4 months in group A. Objective response rate of 46.7% was observed in group B. The 1-year survival rate was 16.7% and the median survival duration was 6.4 months in group B. Myelosuppression was the major dose-limiting toxicity and thromboeytopenia was more frequent in group A. Leukopenia was significant in group B. Conclusion The GP combination is effective and safe in advanced non-small-cell lung cancer.